posted on 2023-12-18, 12:40authored byMarika Turek, Ewa Różycka-Sokołowska, Krzysztof Owsianik, Piotr Bałczewski
Sartans
(angiotensin II receptor blockers, ARBs), drugs used in
the treatment of hypertension, play a principal role in addressing
the global health challenge of hypertension. In the past three years,
their potential use has expanded to include the possibility of their
application in the treatment of COVID-19 and neurodegenerative diseases
(80 clinical studies worldwide). However, their therapeutic efficacy
is limited by their poor solubility and bioavailability, prompting
the need for innovative approaches to improve their pharmaceutical
properties. This review discusses methods of co-crystallization and
co-amorphization of sartans with nonpolymeric, low molecular, and
stabilizing co-formers, as a promising strategy to synthesize new
multipurpose drugs with enhanced pharmaceutical properties. The solid-state
forms have demonstrated the potential to address the poor solubility
limitations of conventional sartan formulations and offer new opportunities
to develop dual-active drugs with broader therapeutic applications.
The review includes an in-depth analysis of the co-crystal and co-amorphous
forms of sartans, including their properties, possible applications,
and the impact of synthetic methods on their pharmacokinetic properties.
By shedding light on the solid forms of sartans, this article provides
valuable insights into their potential as improved drug formulations.
Moreover, this review may serve as a valuable resource for designing
similar solid forms of sartans and other drugs, fostering further
advances in pharmaceutical research and drug development.